Haehling, Stephan von

[["dc.bibliographiccitation.firstpage","325"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","334"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Rozentryt, Piotr"],["dc.contributor.author","Niedziela, Jacek T."],["dc.contributor.author","Hudzik, Bartosz"],["dc.contributor.author","Lekston, Andrzej"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Jankowska, Ewa A."],["dc.contributor.author","Nowak, Jolanta"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Partyka, Robert"],["dc.contributor.author","Rywik, Tomasz"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Poloński, Lech"],["dc.date.accessioned","2019-07-09T11:42:02Z"],["dc.date.available","2019-07-09T11:42:02Z"],["dc.date.issued","2015"],["dc.description.abstract","Background A higher serum phosphate level is associated with worse outcome. Energy-demanding intracellular transport of phosphate is needed to secure anion bioavailability. In heart failure (HF), energy starvation may modify intracellular and serum levels of phosphate. We analysed determinants of serum phosphates in HF and assessed if catabolic/anabolic balance (CAB) was associated with elevation of serum phosphate. Methods We retrospectively reviewed data from 1029 stable patients with HF and have calculated negative (loss) and positive (gain) components of weight change from the onset of HF till index date. The algebraic sum of these components was taken as CAB. The univariate and multivariable predictors of serum phosphorus were calculated. In quintiles of CAB, we have estimated odds ratios for serum phosphorus above levels previously identified to increase risk of mortality. As a reference, we have selected a CAB quintile with similar loss and gain. Results Apart from sex, age, and kidney function, we identified serum sodium, N-terminal fragment of pro-brain-type natriuretic peptide, and CAB as independent predictors of serum phosphorus. The odds for serum phosphorus above thresholds found in literature to increase risk were highest in more catabolic patients. In most catabolic quintile relative to neutral balance, the odds across selected phosphorus thresholds rose, gradually peaking at 1.30 mmol/L with a value of 3.29 (95% confidence interval: 2.00–5.40, P < 0.0001) in an unadjusted analysis and 2.55 (95% confidence interval: 1.38–2.72, P = 0.002) in a fully adjusted model. Conclusions Metabolic status is an independent determinant of serum phosphorus in HF. Higher catabolism is associated with serum phosphorus above mortality risk-increasing thresholds."],["dc.identifier.doi","10.1002/jcsm.12026"],["dc.identifier.pmid","26672973"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12707"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58571"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/241558/EU//SICA-HF"],["dc.relation.euproject","SICA-HF"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","278"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.bibliographiccitation.lastpage","286"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Calvani, Riccardo"],["dc.contributor.author","Marini, Federico"],["dc.contributor.author","Cesari, Matteo"],["dc.contributor.author","Tosato, Matteo"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Miller, Ram R."],["dc.contributor.author","Bernabei, Roberto"],["dc.contributor.author","Landi, Francesco"],["dc.contributor.author","Marzetti, Emanuele"],["dc.date.accessioned","2019-07-09T11:42:33Z"],["dc.date.available","2019-07-09T11:42:33Z"],["dc.date.issued","2015-12-01"],["dc.description.abstract","Physical frailty and sarcopenia are two common and largely overlapping geriatric conditions upstream of the disabling cascade. The lack of a unique operational definition for physical frailty and sarcopenia and the complex underlying pathophysiology make the development of biomarkers for these conditions extremely challenging. Indeed, the current definitional ambiguities of physical frailty and sarcopenia, together with their heterogeneous clinical manifestations, impact the accuracy, specificity, and sensitivity of individual biomarkers proposed so far. In this review, the current state of the art in the development of biomarkers for physical frailty and sarcopenia is presented. A novel approach for biomarker identification and validation is also introduced that moves from the 'one fits all' paradigm to a multivariate methodology."],["dc.identifier.doi","10.1002/jcsm.12051"],["dc.identifier.pmid","26675566"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13564"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58691"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Biomarkers for physical frailty and sarcopenia: state of the science and future developments."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","403"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","412"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Berger, David"],["dc.contributor.author","Bloechlinger, Stefan"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Takala, Jukka"],["dc.contributor.author","Z'Graggen, Werner J."],["dc.contributor.author","Schefold, Joerg C."],["dc.date.accessioned","2018-11-07T10:09:30Z"],["dc.date.available","2018-11-07T10:09:30Z"],["dc.date.issued","2016"],["dc.description.abstract","Muscular weakness and muscle wasting may often be observed in critically ill patients on intensive care units (ICUs) and may present as failure to wean from mechanical ventilation. Importantly, mounting data demonstrate that mechanical ventilation itself may induce progressive dysfunction of the main respiratory muscle, i.e. the diaphragm. The respective condition was termed ventilator-induced diaphragmatic dysfunction' (VIDD) and should be distinguished from peripheral muscular weakness as observed in ICU-acquired weakness (ICU-AW)'. Interestingly, VIDD and ICU-AW may often be observed in critically ill patients with, e.g. severe sepsis or septic shock, and recent data demonstrate that the pathophysiology of these conditions may overlap. VIDD may mainly be characterized on a histopathological level as disuse muscular atrophy, and data demonstrate increased proteolysis and decreased protein synthesis as important underlying pathomechanisms. However, atrophy alone does not explain the observed loss of muscular force. When, e.g. isolated muscle strips are examined and force is normalized for cross-sectional fibre area, the loss is disproportionally larger than would be expected by atrophy alone. Nevertheless, although the exact molecular pathways for the induction of proteolytic systems remain incompletely understood, data now suggest that VIDD may also be triggered by mechanisms including decreased diaphragmatic blood flow or increased oxidative stress. Here we provide a concise review on the available literature on respiratory muscle weakness and VIDD in the critically ill. Potential underlying pathomechanisms will be discussed before the background of current diagnostic options. Furthermore, we will elucidate and speculate on potential novel future therapeutic avenues."],["dc.identifier.doi","10.1002/jcsm.12108"],["dc.identifier.isi","000383753900004"],["dc.identifier.pmid","27030815"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13783"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39664"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Dysfunction of respiratory muscles in critically ill patients on the intensive care unit"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","956"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","961"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Bauer, Juergen"],["dc.contributor.author","Morley, John E."],["dc.contributor.author","Schols, Annemie M.W.J."],["dc.contributor.author","Ferrucci, Luigi"],["dc.contributor.author","Cruz‐Jentoft, Alfonso J."],["dc.contributor.author","Dent, Elsa"],["dc.contributor.author","Baracos, Vickie E."],["dc.contributor.author","Crawford, Jeffrey A."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Heymsfield, Steven B."],["dc.contributor.author","Jatoi, Aminah"],["dc.contributor.author","Kalantar‐Zadeh, Kamyar"],["dc.contributor.author","Lainscak, Mitja"],["dc.contributor.author","Landi, Francesco"],["dc.contributor.author","Laviano, Alessandro"],["dc.contributor.author","Mancuso, Michelangelo"],["dc.contributor.author","Muscaritoli, Maurizio"],["dc.contributor.author","Prado, Carla M."],["dc.contributor.author","Strasser, Florian"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Coats, Andrew J.S."],["dc.contributor.author","Anker, Stefan D."],["dc.date.accessioned","2020-12-10T14:06:45Z"],["dc.date.available","2020-12-10T14:06:45Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/jcsm.12483"],["dc.identifier.eissn","2190-6009"],["dc.identifier.issn","2190-5991"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16637"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70011"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Sarcopenia: A Time for Action. An SCWD Position Paper"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Suzuki, Tsuyoshi"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Haehling, Stephan von"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-08T12:29:23Z"],["dc.date.accessioned","2021-10-27T13:21:17Z"],["dc.date.available","2019-07-08T12:29:23Z"],["dc.date.available","2021-10-27T13:21:17Z"],["dc.date.issued","2019"],["dc.description.abstract","Background: Medroxyprogesterone (MPA) and megestrol acetate (MA) are synthetic progesterone derivates. Progestagen is an approved drug for cancer cachexia in the USA and some Europe. These agents have been described to increase appetite and to lead to weight gain. However, the effects on survival are still unknown. The aim of this study was to evaluate the effects of progesterone on survival, cardiac function as well as appetite and body weight in the Yoshida hepatoma AH‐130 rat cancer cachexia model. Methods: In this study the effects of progesterone were tested in cachectic tumor bearing rats. Rats were treated with 0.5, 5 or 50mg/kg/d, respectively or placebo daily, starting one day after tumor inoculation for a period of 16 days. Cardiac function was analyzed by echocardiography at baseline and at day 11. Food intake was assessed before tumor inoculation and at day 11. Body weight and body composition were evaluated at the beginning and the end of study or day of euthanasia. Results: Survival was significantly improved by 5 mg/kg/d (HR: 0.48, 95%CI: 0.24‐0.95, p=0.0356). However, there was no significant difference between the progesterone treatment groups compared to placebo in body weight change and body composition, as well as food intake on day 11. Cardiac function also showed no significant difference compared to placebo. Conclusion: Progesterone improves survival, but has no beneficial effects on cardiac function, body weight and food intake in this aggressive hepatoma cancer cachexia rat model. Further studies are needed to elucidate the mechanism of the survival benefit."],["dc.description.sponsorship","Open Access-Publikationsfonds 2019"],["dc.identifier.doi","10.1002/rco2.11"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16258"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92008"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Progesterone improves survival in hepatoma cachexia rat model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Lipids in Health and Disease"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Bielecka-Dabrowa, Agata"],["dc.contributor.author","Bytyçi, Ibadete"],["dc.contributor.author","Von Haehling, Stephan"],["dc.contributor.author","Anker, Stefan"],["dc.contributor.author","Jozwiak, Jacek"],["dc.contributor.author","Rysz, Jacek"],["dc.contributor.author","Hernandez, Adrian V."],["dc.contributor.author","Bajraktari, Gani"],["dc.contributor.author","Mikhalidis, Dimitri P."],["dc.contributor.author","Banach, Maciej"],["dc.date.accessioned","2020-12-10T18:38:59Z"],["dc.date.available","2020-12-10T18:38:59Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s12944-019-1135-z"],["dc.identifier.eissn","1476-511X"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16859"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77502"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2303"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Albrecht, Annemarie"],["dc.contributor.author","Porthun, Jan"],["dc.contributor.author","Eucker, Jan"],["dc.contributor.author","Coats, Andrew J.S."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Pezzutto, Antonio"],["dc.contributor.author","Karakas, Mahir"],["dc.contributor.author","Riess, Hanno"],["dc.contributor.author","Keller, Ulrich"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Landmesser, Ulf"],["dc.contributor.author","Haverkamp, Wilhelm"],["dc.contributor.author","Anker, Stefan D."],["dc.date.accessioned","2021-07-05T15:00:42Z"],["dc.date.available","2021-07-05T15:00:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Aims: It is largely unknown whether cancer patients seen in routine care show ventricular arrhythmias in 24 h electrocardiograms (ECGs), and whether when they are detected they carry prognostic relevance. Methods and Results: We included 261 consecutive cancer patients that were referred to the department of cardiology for 24 h ECG examination and 35 healthy controls of similar age and sex in the analysis. To reduce selection bias, cancer patients with known left ventricular ejection fraction <45% were not included in the analysis. Non–sustained ventricular tachycardia (NSVT) episodes of either ≥3 and ≥4 beats duration were more frequent in cancer patients than controls (17% vs. 0%, p = 0.0008; 10% vs. 0%, p = 0.016). Premature ventricular contractions (PVCs)/24 h were not more frequent in cancer patients compared to controls (median (IQR), 26 (2–360) vs. 9 (1–43), p = 0.06; ≥20 PVCs 53% vs. 37%, p = 0.07). During follow-up, (up to 7.2 years, median 15 months) of the cancer patients, 158 (61%) died (1-/3-/5-year mortality rates: 45% [95%CI 39–51%], 66% [95%CI 59–73%], 73% [95%CI 64–82%]). Both non-sustained ventricular tachycardia of ≥4 beats and ≥20 PVCs/24 h independently predicted mortality in univariate and multivariate survival analyses, adjusted for all other univariate predictors of mortality as well as relevant clinical factors, including cancer stage and type, performance status (ECOG), prior potentially cardiotoxic anti-cancer drug therapy, coronary artery disease, potassium concentration, and haemoglobin (multivariate adjusted hazard ratios: NSVT ≥4 beats [HR 1.76, p = 0.022], ≥20 PVCs/24 h [HR 1.63, p < 0.0064]). Conclusions: NSVT ≥4 beats and ≥20 PVCs/day seen in routine 24 h ECGs of patients with cancer carry prognostic relevance."],["dc.description.abstract","Aims: It is largely unknown whether cancer patients seen in routine care show ventricular arrhythmias in 24 h electrocardiograms (ECGs), and whether when they are detected they carry prognostic relevance. Methods and Results: We included 261 consecutive cancer patients that were referred to the department of cardiology for 24 h ECG examination and 35 healthy controls of similar age and sex in the analysis. To reduce selection bias, cancer patients with known left ventricular ejection fraction <45% were not included in the analysis. Non–sustained ventricular tachycardia (NSVT) episodes of either ≥3 and ≥4 beats duration were more frequent in cancer patients than controls (17% vs. 0%, p = 0.0008; 10% vs. 0%, p = 0.016). Premature ventricular contractions (PVCs)/24 h were not more frequent in cancer patients compared to controls (median (IQR), 26 (2–360) vs. 9 (1–43), p = 0.06; ≥20 PVCs 53% vs. 37%, p = 0.07). During follow-up, (up to 7.2 years, median 15 months) of the cancer patients, 158 (61%) died (1-/3-/5-year mortality rates: 45% [95%CI 39–51%], 66% [95%CI 59–73%], 73% [95%CI 64–82%]). Both non-sustained ventricular tachycardia of ≥4 beats and ≥20 PVCs/24 h independently predicted mortality in univariate and multivariate survival analyses, adjusted for all other univariate predictors of mortality as well as relevant clinical factors, including cancer stage and type, performance status (ECOG), prior potentially cardiotoxic anti-cancer drug therapy, coronary artery disease, potassium concentration, and haemoglobin (multivariate adjusted hazard ratios: NSVT ≥4 beats [HR 1.76, p = 0.022], ≥20 PVCs/24 h [HR 1.63, p < 0.0064]). Conclusions: NSVT ≥4 beats and ≥20 PVCs/day seen in routine 24 h ECGs of patients with cancer carry prognostic relevance."],["dc.identifier.doi","10.3390/cancers13102303"],["dc.identifier.pii","cancers13102303"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87884"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","965512"],["dc.bibliographiccitation.journal","Frontiers in Cardiovascular Medicine"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Evertz, Ruben"],["dc.contributor.author","Schulz, Alexander"],["dc.contributor.author","Lange, Torben"],["dc.contributor.author","Backhaus, Sören J."],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Kowallick, Johannes T."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schuster, Andreas"],["dc.date.accessioned","2022-10-04T10:21:43Z"],["dc.date.available","2022-10-04T10:21:43Z"],["dc.date.issued","2022"],["dc.description.abstract","Background\r\n The risk of myocarditis after mRNA vaccination against COVID-19 has emerged recently. Current evidence suggests that young male patients are predominantly affected. In the majority of the cases, only mild symptoms were observed. However, little is known about cardiac magnetic resonance (CMR) imaging patterns in mRNA-related myocarditis and their differences when compared to classical viral myocarditis in the acute phase of inflammation.\r\n \r\n \r\n Methods and results\r\n \r\n In total, 10 mRNA vaccination-associated patients with myocarditis were retrospectively enrolled in this study and compared to 10 patients suffering from viral myocarditis, who were matched for age, sex, comorbidities, and laboratory markers. All patients (\r\n n\r\n = 20) were hospitalized and underwent a standardized clinical examination, as well as an echocardiography and a CMR. Both, clinical and imaging findings and, in particular, functional and volumetric CMR assessments, as well as detailed tissue characterization using late gadolinium enhancement and T1 + T2-weighted sequences, were compared between both groups. The median age of the overall cohort was 26 years (group 1: 25.5; group 2: 27.5;\r\n p\r\n = 0.57). All patients described chest pain as the leading reason for their initial presentation. CMR volumetric and functional parameters did not differ significantly between both groups. In all cases, the lateral left ventricular wall showed late gadolinium enhancement without significant differences in terms of the localization or in-depth tissue characterization (late gadolinium enhancement [LGE] enlargement: group 1: 5.4%; group 2: 6.5%;\r\n p\r\n = 0.14; T2 global/maximum value: group 1: 38.9/52 ms; group 2: 37.8/54.5 ms;\r\n p\r\n = 0.79 and\r\n p\r\n = 0.80).\r\n \r\n \r\n \r\n Conclusion\r\n This study yielded the first evidence that COVID-19 mRNA vaccine-associated myocarditis does not show specific CMR patterns during the very acute stage in the most affected patient group of young male patients. The observed imaging markers were closely related to regular viral myocarditis in our cohort. Additionally, we could not find any markers implying adverse outcomes in this relatively little number of patients; however, this has to be confirmed by future studies that will include larger sample sizes."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fcvm.2022.965512"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114481"],["dc.notes.intern","DOI-Import GROB-600"],["dc.relation.eissn","2297-055X"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Cardiovascular magnetic resonance imaging patterns of acute COVID-19 mRNA vaccine-associated myocarditis in young male patients: A first single-center experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","135"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neuroendocrinology"],["dc.bibliographiccitation.lastpage","144"],["dc.bibliographiccitation.volume","104"],["dc.contributor.author","Pape, Ulrich-Frank"],["dc.contributor.author","Fusch, Gerhard"],["dc.contributor.author","Fischer, Christian"],["dc.contributor.author","Jann, Henning"],["dc.contributor.author","Baur, Alexander"],["dc.contributor.author","Arsenic, Ruza"],["dc.contributor.author","Wiedenmann, Bertram"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Pavel, Marianne"],["dc.contributor.author","Schefold, Joerg C."],["dc.contributor.author","Pschowski, René"],["dc.date.accessioned","2018-11-07T10:29:33Z"],["dc.date.available","2018-11-07T10:29:33Z"],["dc.date.issued","2017"],["dc.description.abstract","Background/Aims: Data from a considerable number of malignancies demonstrate that depletion of the essential amino acid tryptophan via induction of the immunoregulatory enzyme indoleamine-2,3-dioxygenase (IDO) serves as an important tumour escape strategy and is of prognostic importance. Here we investigate the predictive value of the activity of IDO as well as levels of tryptophan and respective downstream catabolites in a large cohort of patients with neuroendocrine neoplasms (NEN). Methods: 142 consecutive Caucasian patients (62 male, aged 60.3 +/- 11.9 years) with histologically confirmed NEN were systematically analysed in a retrospective blinded end point analysis. Patients were followed up for a mean period of about 3.9 +/- 1.9 years. Clinical outcome, levels of established biomarkers, and tryptophan degradation markers (assessed using tandem mass spectrometry) including estimated IDO activity were recorded. Cox proportional hazards regression models were performed for the assessment of prognostic power. Results: We found that baseline tryptophan levels were significantly lower and IDO activity was significantly increased in non-survivors. The risk for death inclined stepwise and was highest in patients in the upper tertile of IDO activity. Cox proportional regression models identified IDO activity as an independent predictor of death. Conclusions: In this retrospective analysis, we observed that baseline activity of the immunoregulatory enzyme IDO was significantly increased in non-survivors. IDO activity was identified as an independent predictor of death in this cohort of NEN patients. Whether IDO activity or tryptophan depletion serves to guide future therapeutic interventions in NEN remains to be established. (C) 2016 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000445191"],["dc.identifier.isi","000390556400004"],["dc.identifier.pmid","26954941"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43663"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0194"],["dc.relation.issn","1423-0194"],["dc.relation.issn","0028-3835"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Increased Activity of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","355"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.bibliographiccitation.lastpage","365"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Stewart Coats, Andrew J."],["dc.contributor.author","Ho, Gwo Fuang"],["dc.contributor.author","Prabhash, Kumar"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Tilson, Julia"],["dc.contributor.author","Brown, Richard"],["dc.contributor.author","Beadle, John"],["dc.contributor.author","Anker, Stefan D."],["dc.date.accessioned","2019-07-09T11:42:31Z"],["dc.date.available","2019-07-09T11:42:31Z"],["dc.date.issued","2016-06-01"],["dc.description.abstract","BACKGROUND: Cancer cachexia is a major cause of morbidity and mortality with no widely approved treatment. METHODS: The ACT-ONE trial is a randomized, double-blind, parallel group, placebo-controlled, phase II multicentre trial in patients (25-80 years) with stages III or IV colorectal cancer or non-small cell lung cancer-related cachexia that tested two doses of espindolol (a novel non-selective β blocker with central 5-HT1a and partial β2 receptor agonist effects). The primary endpoint was the difference in the rate of weight change over 16 weeks (linear mixed-effect model for repeated measures) between high-dose espindolol and placebo. RESULTS: Eighty-seven patients were randomized centrally in blocks in a ratio 3:2:1 [42 high dose, 10 mg twice daily (bd):31 placebo:14 low dose, 2.5 mg bd]. High-dose espindolol produced a statistically and clinically significant weight gain (+0.54 kg/4 weeks, 95% CI 0.38-0.70) compared with a weight loss on placebo (-0.21 kg/4 weeks, 95% CI -0.37-0.05); P < 0.0001. High-dose espindolol produced a statistically significant increase in lean body mass, whilst changes in fat mass were neutral. Hand grip strength significantly (high dose -1.15 ± 0.7 kg, placebo -3.51 ± 0.8 kg change per 4 weeks; P = 0.0134), stair climbing power, and 6-min walk test non-significantly were all directionally in favour of high-dose espindolol. There were no clinically significant differences in safety signals or survival between treatment groups, although a numerical excess of dyspnoea was seen with high-dose espindolol (19.1%) compared with placebo (3.2%). CONCLUSIONS: This positive trial showed that espindolol 10 mg bd significantly reversed weight loss, improved fat free mass, and maintained fat mass in advanced colorectal cancer and non-small cell lung cancer-related cachexia. This was associated with a significant improvement in handgrip strength, supporting the further investigation of 10 mg bd espindolol for the treatment of cancer cachexia. Although not powered to look at dose response, most treatment effects for low dose lay between high dose and placebo, suggesting that there may be a dose response in the effects of espindolol."],["dc.identifier.doi","10.1002/jcsm.12126"],["dc.identifier.pmid","27386169"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58685"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]